MTNB

SEC source: 0001493152-19-016455 · ownership.xml · derivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,416

Underlying: Common Stock · 107,416 shares

Expires 2029-11-01

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0001493152-19-014914 · ownership.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,924

F1 · shares: On September 30, 2019, the Reporting Person was issued 25,179 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 4

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504,049

F3 · shares: On September 30, 2019, the Reporting Person was issued 38,066 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-19-014910 · ownership.xml · nonDerivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 606,898

F1 · shares: On September 30, 2019, the Reporting Person was issued 29,739 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-19-000725 · matinasbio_fm4aug202019.xml · nonDerivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,292

SEC source: 0000905718-19-000719 · matinasbio_fm4aug192019.xml · nonDerivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,292

SEC source: 0000905718-19-000718 · matinasbio_fm4aug192019.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 804,392

F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.69 to $0.70, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0000905718-19-000721 · matinasbio_fm4aug192019.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 786,511

F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.6785 to $0.6990, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0000905718-19-000714 · matinas_fm4aug162019.xml · nonDerivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

SEC source: 0001493152-19-014911 · ownership.xml · derivative · entry 10

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.expiration_date: Converts automatically into Common Stock upon the earlier of (i) notice by the Issuer to the holders that the Issuer elected to convert all outstanding shares of Class A Preferred, (ii) July 29, 2019, (iii) the approval of the Issuer's MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of the Issuer's MAT2501 product candidate.

SEC source: 0001493152-19-014915 · ownership.xml · derivative · entry 8

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.expiration_date: Converts automatically into Common Stock upon the earlier of (i) notice by the Issuer to the holders that the Issuer elected to convert all outstanding shares of Class A Preferred, (ii) July 29, 2019, (iii) the approval of the Issuer's MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of the Issuer's MAT2501 product candidate.

SEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 2

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,052,392

F1 · kind: Stock dividend, payable to all holders of record of Series A Preferred Stock of 2.4 shares of Common Stock for each share of Series A Preferred Stock.

SEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 993,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 2

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 445,983

F1 · kind: Stock dividend, payable to all holders of record of Series A Preferred Stock of 2.4 shares of Common Stock for each share of Series A Preferred Stock.

SEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 397,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001493152-19-010198 · ownership.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,745

F1 · shares: On June 30, 2019, the Reporting Person was issued 18,524 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-19-010196 · ownership.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,983

F1 · shares: On June 30, 2019, the Reporting Person was issued 28,005 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-19-010200 · ownership.xml · nonDerivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 577,159

F1 · shares: On June 30, 2019, the Reporting Person was issued 21,879 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 4

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by AKS Family Partners LP

Disclosed balance after: 3,256,483

F2 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock.

F3 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.

SEC source: 0001493152-19-014914 · ownership.xml · nonDerivative · entry 2

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,124

F2 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock

SEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 3

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 465,983

F2 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-19-014910 · ownership.xml · nonDerivative · entry 2

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 609,298

F2 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-19-016453 · ownership.xml · nonDerivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,692

F1 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-20-000125 · ownership.xml · nonDerivative · entry 1

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,426,565

F1 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-20-000116 · ownership.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 789,511

F1 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock.

SEC source: 0001493152-19-009354 · ownership.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by AKS Family Partners LP

Disclosed balance after: 3,239,483

F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.

SEC source: 0001493152-19-009097 · ownership.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by AKS Family Partners LP

Disclosed balance after: 3,224,483

F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.7966 to $0.8021, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.

SEC source: 0001493152-19-009099 · ownership.xml · nonDerivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 771,861

F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.7929 to $0.8025, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001493152-19-009014 · ownership.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by AKS Family Partners LP

Disclosed balance after: 3,204,483

F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.79 to $0.83, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.

SEC source: 0001493152-19-008941 · ownership.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by AKS Family Partners LP

Disclosed balance after: 3,189,483

F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.

SEC source: 0001493152-19-008568 · ownership.xml · nonDerivative · entry 1

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by AKS Family Partners LP

Disclosed balance after: 3,169,483

F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.92 to $0.95, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.

SEC source: 0001493152-19-007948 · ownership.xml · nonDerivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

SEC source: 0001493152-19-007949 · ownership.xml · nonDerivative · entry 5

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by AKS Family Partners LP

Disclosed balance after: 3,089,483

F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.92 to $0.95, inclusive. Upon request of the SEC staff, the reporting person will provide full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose.

SEC source: 0001493152-19-007947 · ownership.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad and Judith Conrad, Trustees

Disclosed balance after: 172,959

F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.9563 to $0.9650, inclusive. Upon request of the SEC staff, the reporting person will provide full information regarding the number of shares purchased at each separate price.

SEC source: 0000905718-19-000329 · matinasbio_fm4mar312019.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,221

F1 · shares: On March 31, 2019, the Reporting Person was issued 14,565 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-19-000327 · conrad_fm4feb82019.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,019

F1 · shares: On March 31, 2019, the Reporting Person was issued 22,019 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-19-000325 · matinas_fm4mar312019.xml · nonDerivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 555,280

F1 · shares: On March 31, 2019, the Reporting Person was issued 17,202 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0001493152-19-014911 · ownership.xml · nonDerivative · entry 3

STERN ADAM K · CIK 0001403497 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,058,992

SEC source: 0000905718-19-000260 · matinas_form4feb252019.xml · derivative · entry 1

Ferguson James J. III · CIK 0001769041 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2029-02-24

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 25, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 31, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0000905718-19-000108 · mannino-matinasfm4_feb112019.xml · derivative · entry 1

MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-02-10

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0000905718-19-000114 · matinasbiofm4_feb112019.xml · derivative · entry 1

Kucinski Keith A · CIK 0001763405 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2029-02-10

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0000905718-19-000112 · matinasbiofm4_feb112019.xml · derivative · entry 1

Matkovits Theresa · CIK 0001745393 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2029-02-10

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0000905718-19-000110 · jabbour-matinasfm4_feb112019.xml · derivative · entry 1

Jabbour Jerome D · CIK 0001698838 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2029-02-10

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0000905718-19-000106 · conrad_fm4feb82019.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

SEC source: 0000905718-19-000023 · ownership.xml · derivative · entry 1

Kucinski Keith A · CIK 0001763405 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2029-01-02

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 62,500 shares on January 2, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

SEC source: 0000905718-19-000017 · ownership.xml · nonDerivative · entry 1

Ende Eric J · CIK 0001494386 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,091

F1 · shares: On December 31, 2018, the Reporting Person was issued 15,022 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-19-000018 · ownership.xml · nonDerivative · entry 1

WIKLER MATTHEW · CIK 0001195414 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,656

F1 · shares: On December 31, 2018, the Reporting Person was issued 26,681 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-19-000020 · ownership.xml · nonDerivative · entry 1

CONRAD HERBERT J · CIK 0001218815 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,032,903

F1 · shares: On December 31, 2018, the Reporting Person was issued 40,337 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-19-000019 · ownership.xml · nonDerivative · entry 1

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 538,078

F1 · shares: On December 31, 2018, the Reporting Person was issued 31,513 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

SEC source: 0000905718-18-000905 · ownership.xml · derivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,299

Underlying: Common Stock · 128,299 shares

Expires 2028-10-31

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.